Detalhe da pesquisa
1.
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Ann Oncol
; 34(8): 714-722, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182801
2.
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
Ann Oncol
; 30(11): 1831-1839, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31501887
3.
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.
Ann Oncol
; 29(5): 1130-1140, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29635316
4.
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
Ann Oncol
; 28(11): 2813-2819, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045520
5.
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Ann Oncol
; 28(10): 2526-2532, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961833
6.
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Ann Oncol
; 27(2): 318-23, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26598548
7.
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.
Ann Oncol
; 27(5): 908-13, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26884588
8.
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
Ann Oncol
; 27(8): 1585-93, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27084954
9.
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.
Ann Oncol
; 26(1): 198-205, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25361984
10.
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
Ann Oncol
; 25(9): 1813-1820, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24928832
11.
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
Ann Oncol
; 24(3): 769-76, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23104721
12.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
Oral Oncol
; 147: 106587, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37925894
13.
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
Ann Oncol
; 22(10): 2304-9, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21330337
14.
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
Ann Oncol
; 22(11): 2501-2507, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21385883
15.
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Ann Oncol
; 19(10): 1787-94, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18539617
16.
Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.
Dis Esophagus
; 21(6): 514-21, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18840136
17.
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
Cancer Chemother Pharmacol
; 74(6): 1261-70, 2014 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25315258
18.
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
Clin Pharmacol Ther
; 96(1): 27-35, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24637941
19.
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
Oral Oncol
; 49(3): 277-82, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23102863
20.
Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.
Oral Oncol
; 49(6): 525-33, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23490885